- Home
- VLCN vs ENVB Comparison
VLCN vs ENVB Comparison
Compare VLCN & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLCN
- ENVB
- Stock Information
- Founded
- VLCN 2020
- ENVB 1994
- Country
- VLCN United States
- ENVB United States
- Employees
- VLCN N/A
- ENVB N/A
- Industry
- VLCN Auto Manufacturing
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- VLCN Consumer Discretionary
- ENVB Health Care
- Exchange
- VLCN Nasdaq
- ENVB Nasdaq
- Market Cap
- VLCN 2.6M
- ENVB 3.1M
- IPO Year
- VLCN 2021
- ENVB N/A
- Fundamental
- Price
- VLCN $6.95
- ENVB $1.25
- Analyst Decision
- VLCN
- ENVB Strong Buy
- Analyst Count
- VLCN 0
- ENVB 1
- Target Price
- VLCN N/A
- ENVB $10.00
- AVG Volume (30 Days)
- VLCN 52.1K
- ENVB 184.2K
- Earning Date
- VLCN 08-05-2025
- ENVB 08-11-2025
- Dividend Yield
- VLCN N/A
- ENVB N/A
- EPS Growth
- VLCN N/A
- ENVB N/A
- EPS
- VLCN N/A
- ENVB N/A
- Revenue
- VLCN $3,739,692.00
- ENVB N/A
- Revenue This Year
- VLCN N/A
- ENVB N/A
- Revenue Next Year
- VLCN N/A
- ENVB N/A
- P/E Ratio
- VLCN N/A
- ENVB N/A
- Revenue Growth
- VLCN 19.70
- ENVB N/A
- 52 Week Low
- VLCN $4.40
- ENVB $1.01
- 52 Week High
- VLCN $448.00
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- VLCN 63.79
- ENVB 44.83
- Support Level
- VLCN $5.50
- ENVB $1.20
- Resistance Level
- VLCN $6.53
- ENVB $1.35
- Average True Range (ATR)
- VLCN 0.62
- ENVB 0.07
- MACD
- VLCN 0.18
- ENVB 0.01
- Stochastic Oscillator
- VLCN 98.52
- ENVB 38.89
About VLCN Volcon Inc. Common stock
Volcon Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.